Microbix expands pandemic test controls portfolio
Nov. 22, 2021—Microbix Biosystems has expanded its portfolio of Quality Assessment Products to include controls that support PCR tests for four major variants of concern of SARS-CoV-2.
Webinars and Sponsored Roundtables — Register Now
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Cobas 5800 molecular Dx system launched in CE markets
Nov. 18, 2021—Roche launched its Cobas 5800 system in countries accepting the CE mark.
LumiraDx’s COVID-19 antigen test gets expanded EUA
Nov. 5, 2021—LumiraDx announced that the FDA’s emergency use authorization for its SARS-CoV-2 antigen test has been expanded to include screening of asymptomatic individuals.
FDA grants EUA for Lighthouse’s COVID-19 assay
Nov. 3, 2021—Lighthouse Lab Services announced that the FDA has granted emergency use authorization for its CovidNow SARS-CoV-2 assay kit. The EUA covers use for symptomatic and asymptomatic patients with a provider’s order.
Bio-Rad launches enhanced Liquichek diabetes control
Nov. 1, 2021—Bio-Rad Laboratories launched an enhanced version of its Liquichek Diabetes Control.
Hologic’s multiplex COVID-19/flu test now available
Oct. 29, 2021—Hologic announced that its Aptima SARS-CoV-2/Flu assay is available for the simultaneous detection and differentiation of three respiratory viruses that can present with overlapping clinical symptoms.
Bio-Rad launches CFX Opus Dx RT-PCR detection systems
Oct. 27, 2021—Bio-Rad Laboratories launched its CFX Opus 96 Dx and CFX Opus 384 Dx systems, real-time PCR detection systems that have been listed with the FDA for IVD testing and that meet the CE-IVD requirement for IVD use in Europe.
Labcon awarded $59.3 million to increase pipette production
Oct. 25, 2021—Labcon North America, a wholly owned subsidiary of Helena Laboratories, has announced a $59.3 million contract award from the U.S. Department of Defense in coordination with the U.S. Department of Health and Human Services.
Hardy Diagnostics releases HardyChrom Candida + auris
Oct. 21, 2021—Hardy Diagnostics has released its HardyChrom Candida + auris, a chromogenic media recommended for the selective isolation and differential identification of Candida species.
LumiraDx submits SARS-CoV-2/flu A/B antigen test for EUA
Oct. 18, 2021—LumiraDx has submitted the LumiraDx SARS-CoV-2 & Flu A/B Test to the Food and Drug Administration for emergency use authorization.